Payment overview · 2025
General Payments
$277,352.21
262 reported records · 16 companies
Healthcare provider profile · identity verified
Dilsher Singh Dhoot, M.D.
Allopathic & Osteopathic Physicians|Ophthalmology|Retina Specialist · SANTA BARBARA, CA · NPI 1508070566
Verified facts
What the public records show
CMS Open Payments records show Dilsher Singh Dhoot, M.D. received $277,352.21 in general payments during 2025 across 262 reported records.
Regeneron Healthcare Solutions, Inc. accounted for 39.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Lumigan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lumigan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $108,237.05 | 39.0% | 85 | 2025 |
| Apellis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $67,626.38 | 24.4% | 63 | 2025 |
| Ocular Therapeutix, Inc. | Unresolved — no canonical attribution shown | $52,398.11 | 18.9% | 49 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18,857.28 | 6.8% | 16 | 2025 |
| Bausch & Lomb Americas Inc. | Unresolved — no canonical attribution shown | $11,556.30 | 4.2% | 9 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $7,688.81 | 2.8% | 12 | 2025 |
| Astellas Pharma Global Development | Unresolved — no canonical attribution shown | $3,692.00 | 1.3% | 1 | 2025 |
| Roche Products Limited | Unresolved — no canonical attribution shown | $3,150.00 | 1.1% | 1 | 2025 |
| Genentech, Inc. | Unresolved — no canonical attribution shown | $2,490.00 | 0.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $873.22 | 0.3% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $234.57 | 0.1% | 7 | 2025 |
| Harrow Eye, LLC | Unresolved — no canonical attribution shown | $221.49 | 0.1% | 5 | 2025 |
| Avirmax Biopharma, Inc | Unresolved — no canonical attribution shown | $178.46 | 0.1% | 2 | 2025 |
| Regeneron Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $68.99 | 0.0% | 2 | 2025 |
| Neurotech Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.02 | 0.0% | 2 | 2025 |
| BioCryst Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.53 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $92,650.26 | 11 |
| Consulting Fee | $73,018.83 | 45 |
| Compensation for serving as faculty or as a speaker for a medical education program | $55,976.00 | 9 |
| Travel and Lodging | $24,955.76 | 75 |
| Honoraria | $23,575.00 | 5 |
| Food and Beverage | $7,176.36 | 117 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EYLEA HD Normalized: eylea hd |
Biological | Regeneron Healthcare Solutions, Inc., Regeneron Pharmaceuticals, Inc. | $107,753.54 | 86 | 2025 |
Source payment records
|
|||||
| Syfovre Normalized: syfovre |
Drug | Apellis Pharmaceuticals, Inc. | $67,236.18 | 59 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $16,012.44 | 13 | 2025 |
Source payment records
|
|||||
| STELLARIS ELITE Normalized: stellaris elite |
Device | Bausch & Lomb Americas Inc. | $11,409.53 | 5 | 2025 |
Source payment records
|
|||||
| Stellaris Normalized: stellaris |
Device | Bausch & Lomb Americas Inc. | $8,471.94 | 6 | 2025 |
Source payment records
|
|||||
| Vabysmo Normalized: vabysmo |
Drug | Genentech USA, Inc., Genentech, Inc. | $5,505.61 | 10 | 2025 |
Source payment records
|
|||||
| Susvimo Normalized: susvimo |
Drug | Genentech USA, Inc., Genentech, Inc. | $4,023.20 | 4 | 2025 |
Source payment records
|
|||||
| Izervay Normalized: izervay |
Drug | Astellas Pharma Global Development, Astellas Pharma US Inc | $3,926.57 | 8 | 2025 |
Source payment records
|
|||||
| ILUVIEN Normalized: iluvien |
Drug | ANI Pharmaceuticals, Inc. | $2,813.47 | 2 | 2025 |
Source payment records
|
|||||
| DEXTENZA Normalized: dextenza |
Drug | Ocular Therapeutix, Inc. | $878.27 | 11 | 2025 |
Source payment records
|
|||||
| OZURDEX Normalized: ozurdex |
Drug | ABBVIE INC. | $746.69 | 3 | 2025 |
Source payment records
|
|||||
| EYLEA Normalized: eylea |
Biological | Regeneron Healthcare Solutions, Inc., Regeneron Pharmaceuticals, Inc. | $621.49 | 3 | 2025 |
Source payment records
|
|||||
| IHEEZO Normalized: iheezo |
Drug | Harrow Eye, LLC | $221.49 | 5 | 2025 |
Source payment records
|
|||||
| XIPERE Normalized: xipere |
Drug | Bausch & Lomb Americas Inc. | $84.36 | 2 | 2025 |
Source payment records
|
|||||
| YUTIQ Normalized: yutiq |
Drug | ANI Pharmaceuticals, Inc. | $31.37 | 1 | 2025 |
Source payment records
|
|||||
| LUMIGAN Normalized: lumigan |
Drug | ABBVIE INC. | $13.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LUMIGAN lumigan |
2025 | Lumigan | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisolone Acetate | Prednisolone Acetate | 343 | 185 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 249 | 100 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 171 | 70 |
| Erythromycin | Erythromycin Base | 165 | 117 |
| Atropine Sulfate | Atropine Sulfate | 143 | 97 |
| Brimonidine Tartrate | Brimonidine Tartrate | 137 | 56 |
| Latanoprost | Latanoprost | 117 | 44 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 101 | 80 |
| Timolol Maleate | Timolol Maleate | 42 | 20 |
| Dorzolamide Hcl | Dorzolamide Hcl | 23 | 14 |
| Moxifloxacin | Moxifloxacin Hcl | 21 | 12 |
| Ofloxacin | Ofloxacin | 17 | 11 |
| Travoprost | Travoprost | 17 | suppressed |
| Fluorometholone | Fluorometholone | 16 | suppressed |
| Loteprednol Etabonate | Loteprednol Etabonate | 15 | suppressed |
| Difluprednate | Difluprednate | 14 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 13 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $277,352.21 · 262 records | Regeneron Healthcare Solutions, Inc. | DEXTENZA, EYLEA, EYLEA HD, IHEEZO, ILUVIEN, Izervay, LUMIGAN, OZURDEX, PURIFIED CORTROPHIN GEL, STELLARIS ELITE, Stellaris, Susvimo, Syfovre, Vabysmo, XIPERE, YUTIQ | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Lumigan play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error